CLINICAL USES OF 2,3—DIMERCAPTOPROPANOL (BAL). I. THE SYSTEMIC TREATMENT OF EXPERIMENTAL ARSENIC POISONING (MAPHARSEN, LEWISITE, PHENYL ARSENOXIDE) WITH BAL

. 1946 Jul;25(4):451–466. doi: 10.1172/JCI101728

CLINICAL USES OF 2,3—DIMERCAPTOPROPANOL (BAL). I. THE SYSTEMIC TREATMENT OF EXPERIMENTAL ARSENIC POISONING (MAPHARSEN, LEWISITE, PHENYL ARSENOXIDE) WITH BAL ^¹

PMCID: PMC435584 PMID: 21001620

These references are in PubMed. This may not be the complete list of references from this article.

Barron E. S., Singer T. P. ENZYME SYSTEMS CONTAINING ACTIVE SULFHYDRYL GROUPS. THE ROLE OF GLUTATHIONE. Science. 1943 Apr 16;97(2520):356–358. doi: 10.1126/science.97.2520.356. [DOI] [PubMed] [Google Scholar]
Luetscher J. A., Eagle H., Longcope W. T., Watson E. B. CLINICAL USES OF 2,3-DIMERCAPTOPROPANOL (BAL). VIII. THE EFFECT OF BAL ON THE EXCRETION OF ARSENIC IN ARSENICAL INTOXICATION. J Clin Invest. 1946 Jul;25(4):534–540. doi: 10.1172/JCI101735. [DOI] [PMC free article] [PubMed] [Google Scholar]
Walker E. Chemical constitution and toxicity. Biochem J. 1928;22(1):292–305. doi: 10.1042/bj0220292. [DOI] [PMC free article] [PubMed] [Google Scholar]
Waters L. L., Stock C. BAL (BRITISH ANTI-LEWISITE). Science. 1945 Dec 14;102(2659):601–606. doi: 10.1126/science.102.2659.601. [DOI] [PubMed] [Google Scholar]